KalVista Pharmaceuticals’ Sebetralstat Shows Promise in Revolutionizing Angioedema Treatment
Late-breaking results from the KONFIDENT phase 3 and open-label KONFIDENT-S extension trials were presented at the European Academy of...
Jon Napitupulu
Artera Unveils Extraordinary AI Cancer Platform, Unveiling the Future of Cancer Treatment
Artera’s multimodal artificial intelligence (MMAI) platform has demonstrated notable prognostic value in prostate and early-stage breast cancer. Studies presented...
Calidi Biotherapeutics $2.1 Million Warrant Exercise
Calidi Biotherapeutics, a biotechnology company focusing on targeted immunotherapies, announced the exercise of warrants for purchasing over 10.6 million...
Livmarli® Positive Opinion by CHMP for Treatment of PFIC in Infants and Toddlers
The European Committee for Medicinal Products for Human Use (CHMP) has granted a positive opinion for LIVMARLI (maralixibat) oral...
Study Results in Metastatic NSCLC Presented at ASCO 2024: Astonishing Breakthrough
The EVOKE-01 study investigated Trodelvy against docetaxel in patients with advanced non-small cell lung cancersmall cell lung cancer (NSCLC)...
Pfizer’s Lorbrena® CROWN Study: Remarkable Milestone for Lung Cancer Patients
A recent Phase 3 CROWN trial has demonstrated the long-term effectiveness of LORBRENA in treating ALK-positive advanced non-small cell...
Revolutionary FDA Clearance Paves Way for Game-Changing Hemophilia B Therapy
Be Biopharma, Inc., a pioneer in developing Engineered B Cell Medicines (BCMs), has received IND clearance from the FDA...
ViVani Medical Unveils Groundbreaking Weight Loss Solution for Pets with OKV-119: A Life-Changing Innovation
A study published in BMC Veterinary Research demonstrates the effectiveness of OKV-119, a miniature drug implant containing exenatide, in...
AI Validation in Massive Bio Clinical Trial: A Revolutionary Breakthrough
The Precision Cancer Consortium (PCC) and Massive Bio have conducted a comprehensive study on the efficacy of Massive Bio’s...
Merck: Phase 3 Trial Success for TNBC Patients
KEYTRUDA (pembrolizumab) has demonstrated promising results in the treatment of high-risk early-stage triple-negative breast cancer (TNBC) in the Phase...